drugset / Trial / NCT05718817
An Open-label Study of XEN1101 in Epilepsy
Phase 3
Enrolling by invitation
880 enrolled
Xenon Pharmaceuticals Inc.
Worldwide Clinical Trials · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years.
Timeline
- Start
- 2023-04-25
- Primary completion
- 2033-04
- Completion
- 2033-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azetukalner | Small molecule | 15 mg | Oral |
| Subject | Azetukalner | Small molecule | 25 mg | Oral |